Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC

Kim, Hye RyunHye RyunKimAwad, Mark MMark MAwadNavarro, AlejandroAlejandroNavarroGottfried, MayaMayaGottfriedPeters, SolangeSolangePetersCsőszi, TiborTiborCsősziCheema, Parneet KParneet KCheemaRodriguez-Abreu, DelvysDelvysRodriguez-AbreuWollner, MirjanaMirjanaWollnerCHIH-HSIN YANGMazieres, JulienJulienMazieresOrlandi, Francisco JFrancisco JOrlandiLuft, AlexanderAlexanderLuftGümüş, MahmutMahmutGümüşKato, TerufumiTerufumiKatoKalemkerian, Gregory PGregory PKalemkerianLuo, YiwenYiwenLuoSantorelli, Melissa LMelissa LSantorelliPietanza, M CatherineM CatherinePietanzaRudin, Charles MCharles MRudin2023-11-292023-11-292023-1126663643https://scholars.lib.ntu.edu.tw/handle/123456789/637405In the phase 3 KEYNOTE-604 study (NCT03066778), pembrolizumab plus etoposide and platinum chemotherapy (EP) significantly (p = 0.0023) improved progression-free survival versus placebo plus EP in previously untreated extensive-stage SCLC (ES-SCLC). We present health-related quality of life (HRQoL) results from KEYNOTE-604.enChemotherapy; Extensive-stage small-cell lung cancer; Health-related quality of life; Patient-reported outcomes; Pembrolizumab[SDGs]SDG3Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLCjournal article10.1016/j.jtocrr.2023.100572379549642-s2.0-85175444083https://api.elsevier.com/content/abstract/scopus_id/85175444083